- Tytuł:
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
- Autorzy:
- Źródło:
- In The Lancet 19-25 February 2022 399(10326):729-740
Czasopismo naukowe